Biochemical and Biophysical Research Communications
Investigation of mitochondrial sequence variants associated with aminoglycoside-induced ototoxicity in South African TB patients on aminoglycosides
Introduction
South Africa is currently facing a major tuberculosis (TB) and multi-drug resistant tuberculosis (MDR-TB) epidemic, and has been ranked 4th among the 22 high-burden TB countries worldwide [1]. MDR-TB, defined as the resistance of Mycobacterium tuberculosis (Mtb) bacillus to at least Isoniazid and Rifampacin, which are the two most powerful first-line drugs, is thought to be a ‘man made’ problem [2]. In the majority of cases, MDR-TB emerges when either a TB patient receives inappropriate treatment which results in the naturally occurring resistant TB bacteria to survive and multiply or because of poor compliance of the TB patient to their treatment. It is estimated that approximately 2.6% of all TB cases are diagnosed as MDR-TB and there are more than 10,000 new MDR-TB cases in South Africa per year [1].
In South Africa, according to the World Health Organization’s (WHO) guidelines, MDR-TB is treated with a number of second-line drugs including the quinolones (Ciprofloxacin, Ofloxacin and Sparfloxacin) and aminoglycosides (Streptomycin, Kanamycin and Amikacin). The second-line drugs are much more costly and more toxic than the first-line drugs [3]. Regardless of the effectiveness of aminoglycosides against bacterial infections, serious toxicity is a major limitation in the usefulness of these drugs [4]. The same spectrum of toxicity is shared by all members of the aminoglycoside family of which the most notable is ototoxicity and nephrotoxicity [5]. Ototoxicity is caused as a result of damage to the outer hair cells in the cochlea and vestibular labyrinth leading to permanent hearing loss in patients hypersensitive to these drugs. Aminoglycoside ototoxicity is recognized by a distinctive pattern of hearing loss starting in the high frequency range (4000–8000 Hz) with lower frequencies only affected later.
Mutations in mitochondrial genes have been associated with increased susceptibility to hearing loss in individuals who receive aminoglycoside therapy. Hearing loss due to aminoglycoside exposure has been identified in a number of families from all over the world [6], [7], [8], [9]. Numerous mutations (including A1555G, C1494T, T1095C, 961delT+insC(n), T961G, A827G and T1291C) have been identified in the mitochondrial MT-RNR1 gene that encodes the human 12S rRNA ribosomal subunit. It has been shown that the A1555G mutation causes increased binding of aminoglycosides to the 12S rRNA ribosomal subunit [10] which results in the disruption of mitochondrial protein synthesis in the cell. All proteins synthesized in the mitochondria are involved in oxidative phosphorylation and the disruption thereof will ultimately lead to death of the cell.
As the incidence of MDR-TB increases in South Africa, the use of aminoglycosides will also increase. Therefore, there is a need for a rapid genetic screening method that is easy, cost effective and high throughput, so that it may be used in a diagnostic setting. This method can potentially be incorporated into the global TB strategy in order to detect these mutations in MDR-TB patients prior to them starting their aminoglycoside therapy. Recently, we have developed such a method based on the SNaPshot multiplex system that can detect six of these mutations in a single reaction [11], [12]. The application of this rapid screening test in clinical practice would aid in identifying susceptible individuals prior to the start of their aminoglycoside treatment therapy thereby potentially lowering the incidence of aminoglycoside-induced hearing loss in South Africa. There are certain precautionary measures that can be applied to minimize the progression of cochlear and vestibular damage in mutation-positive individuals which include avoidance of drugs with synergistic ototoxic effects, reducing therapy time and regular audiological monitoring throughout treatment.
Currently, there is no known data on the incidence of aminoglycoside-induced hearing loss in South Africa. As aminoglycosides are relatively commonly used here, the population of this country is a unique resource to study both the short and long term effects of these drugs on the auditory system and the genetic etiology of aminoglycoside-induced hearing loss. In the present study we investigated the frequencies of six known MT-RNR1 mutations in a group of MDR-TB patients on aminoglycosides as well as controls, and screened for novel pathogenic mutations in the mitochondrial genome.
Section snippets
Materials and methods
Study participants. The study was approved by the Committee for Human Research at the University of Stellenbosch (Protocol number: N05/09/165). A total of 115 mostly MDR-TB patients (63.5% female) were recruited with informed, written consent from the Brooklyn Chest Hospital in Cape Town, South Africa. Inclusion criteria included that the patient had to have received aminoglycosides as part of their treatment and that they had to have normal hearing at entering the study. The study group
Results
Our recently developed SNaPshot screening method was used to determine the frequencies of the previously characterized MT-RNR1 mutations in a group of MDR-TB patients (of which at least a third had developed ototoxicity following exposure to aminoglycosides) as well as control samples (Table 1).
The mutation most frequently associated with aminoglycoside-induced hearing loss, A1555G, was found in approximately 1% of the control samples: in 0.9% of the Black controls and 1.1% of the Afrikaner
Discussion
To date, there are no known statistics on the frequency of the mutations associated with aminoglycoside-induced hearing loss in South Africa. Knowledge about the frequency of these mutations in our populations is imperative in understanding and determining whether certain ethnic or sub-population groups are at increased risk of developing hearing loss due to aminoglycoside exposure.
Using our SNaPshot method we determined that the A1555G mutation was present in 0.9% of the South African Black
Acknowledgements
Our sincere thanks go to the MDR-TB patients at Brooklyn Chest Hospital for their participation in this study. We would like to thank Ms Natalie Venema for patient recruitment and Ms Melissa Du Plessis for DNA extraction. This work was supported by funding from the South African National Research Foundation, the South African Medical Research Council and the Harry Crossley Foundation.
References (27)
- et al.
Very low penetrance of hearing loss in seven Han Chinese pedigrees carrying the deafness-associated 12S rRNA A1555G mutation
Gene
(2007) - et al.
A South African family with the mitochondrial A1555G mutation on haplogroup L0d
Biochem. Biophys. Res. Commun.
(2009) - et al.
Maternally inherited non-syndromic hearing loss associated with mitochondrial 12S rRNA A827G mutation in a Chinese family
Biochem. Biophys. Res. Commun.
(2006) - et al.
Mitochondrial 12S rRNA A827G mutation is involved in the genetic susceptibility to aminoglycoside ototoxicity
Biochem. Biophys. Res. Commun.
(2006) - et al.
A mutation in mitochondrial 12S rRNA, A827G, in Argentinean family with hearing loss after aminoglycoside treatment
Biochem. Biophys. Res. Commun.
(2008) - et al.
Genetic features, clinical phenotypes, and prevalence of sensorineural hearing loss associated with the 961delT mitochondrial mutation
Auris Nasus Larynx
(2005) - et al.
Mitochondrial 12S rRNA susceptibility mutations in aminoglycoside-associated and idiopathic bilateral vestibulopathy
Biochem. Biophys. Res. Commun.
(2008) - et al.
Genetic susceptibility to aminoglycoside ototoxicity: how many are at risk?
Genet. Med.
(2002) - et al.
A new method for analysis of mitochondrial DNA point mutations and assess levels of heteroplasmy
Biochem. Biophys. Res. Commun.
(2006) - World Health Organization Report, 2008. Global tuberculosis control. Surveillance, Planning, Financing....
XDR TB in South Africa – What lies ahead?
SA Fam. Pract.
Responding to market failures in tuberculosis control
Science
Use of antibiotics aminoglycosides
Brit. Med. J.
Cited by (20)
The genetic basis of deafness in populations of African descent
2017, Journal of Genetics and GenomicsCitation Excerpt :This mutation has been detected in low frequency among African populations, including 18 family members of mixed ancestry in South Africa where nine of these family members had profound bilateral post-lingual hearing loss following aminoglycoside use, while the remaining nine were found to be carriers of the mutation but had not received aminoglycosides (Gardner et al., 1997). Human et al. (2010) later conducted a study that included 115 MDR-TB (multi-drug resistant tuberculosis) patients all on aminoglycosides and 439 controls representative of the main ethnic groups in South Africa. Data analysis revealed the presence of homoplasmic mutations in controls (m.1555A>G in 0.9% of Black controls and m.827A>G in 1.1% of Afrikaner controls), suggesting that a significant proportion of the South African population is genetically predisposed to developing aminoglycoside-induced hearing loss.
Miscellaneous antibacterial drugs
2012, Side Effects of Drugs AnnualCitation Excerpt :Bacterial ribosomes share similarity with mitochondrial (mt) ribosomes. Mutations in mt 12S rRNA genes have been associated with increased susceptibility to ototoxicity in individuals receiving aminoglycoside therapy [5c]. The A1555G and C1494T mutations in the human mt 12S rRNA have been associated with aminoglycoside-induced hearing loss worldwide.
Pharmacogenomics and adverse effects of anti-infective drugs in children
2024, Clinical and Experimental Pharmacology and PhysiologyStructural analysis of mitochondrial rRNA gene variants identified in patients with deafness
2023, Frontiers in PhysiologyPharmacokinetics and other risk factors for kanamycin-induced hearing loss in patients with multi-drug resistant tuberculosis
2020, International Journal of AudiologyMitochondrial DNA haplogroup C4 can increase the risk of active tuberculosis disease in Southwest China
2019, International Journal of Tuberculosis and Lung Disease
- 1
These authors contributed equally to this work.